Starpharma is rethinking the science behind conventional oncology approaches through its proprietary drug delivery platform technology called DEP ®
Starpharma (ASX: SPL, OTCQX: SPHRY) is a biopharmaceutical company based in Australia that specializes in developing and commercializing innovative therapeutic products.
Starpharma has become a world leader in dendrimer technology, with a strong portfolio of products, intellectual property, and partnerships.
Led by an accomplished team of professionals in science and business, Starpharma is dedicated to making a positive impact on people’s lives. The Company's technology is based on dendrimers, which are highly customizable and precisely engineered polymers with a wide range of applications in pharmaceuticals and medical products.
Starpharma has developed a technology platform known as DEP ® (Dendrimer Enhanced Product), which utilizes dendrimers to improve the effectiveness and safety of drugs. This innovative approach opens up new possibilities for targeted and controlled drug delivery, leading to increased therapeutic and commercial opportunities. Additionally, the use of DEP ® technology can result in the creation of new intellectual property and an extended patent life for existing drugs.
Starpharma has an impressive pipeline of novel DEP ® drug candidates generated by in-house discovery efforts. Its clinical-stage assets, including DEP ® cabazitaxel, DEP ® docetaxel, and DEP ® irinotecan, are DEP ® modified versions of off-patent chemotherapeutic drugs that have demonstrated improved anti-cancer effects and safety profiles in
Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP ® antibody-drug conjugates (ADCs) and DEP ® radiotheranostics.
The DEP ® technology is highly versatile and flexible in drug formulation, enabling the Company to target a wide range of therapeutics, including small molecules, peptides, proteins, and nucleic acids. It also offers more opportunities for combination therapies and targeting broader cancer indications.
Starpharma has established partnerships with some of the world’s largest pharmaceutical companies, including AstraZeneca, MSD, and Genentech, to develop DEP ® -based products. The Company’s partnership with AstraZeneca is the most advanced and involves the development of AZD0466, a DEP ® version of an AstraZeneca oncology drug that is now undergoing two global Phase 1/2 clinical trials in patients with advanced blood cancers for which treatment options are limited.
In summary, Starpharma's DEP ® platform is a dendrimer-based drug delivery technology that enhances the efficacy, safety, and targeted delivery of various pharmaceutical compounds. DEP ® holds significant optionality and immense potential to improve the treatment of various diseases, particularly cancer, by optimizing drug properties and enabling targeted therapy.
Starpharma has several key milestones on the horizon including upcoming development milestones with partners and results from multiple oncology trials.